<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Blizard Institute of Cell and Molecular</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7BC273D6-7DF3-4DFE-B835-E4C407817CE6"><gtr:id>7BC273D6-7DF3-4DFE-B835-E4C407817CE6</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>MacDonald</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800746"><gtr:id>9A2C4E90-D861-4FD7-AFC0-18AA6F103C16</gtr:id><gtr:title>Inhibitory anti-CD3 antibodies to switch off activated T cells in man</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800746</gtr:grantReference><gtr:abstractText>Many of the common diseases of the developed world are caused by the immune system responding to harmless molecules such as foods or plant materials, or responding to the bodies own tissues. One particular type of immune cell, called a T cell, controls these tissue-damaging responses. This proposal aims to find a way to switch off the disease causing T cells by targeting a molecule on their surface in such a way as to render the cell inactive.</gtr:abstractText><gtr:technicalSummary>Activated T cells responding to exogenous or endogenous antigens lie at the heart of many of the important immune-mediated diseases of the western world. The discovery that unglycosylated anti-CD3 monoclonal antibodies lacking Fc receptor binding activity not only lack the ability to activate T cells, but can deliver a negative signal, has led to the development of otelixuzumab and related molecules, currently in phase III for type I diabetes. It is the aim of this proposal to make a step-wise change in the possible therapeutic use of this antibody by taking advantage of the fact that the gut is the only tissue in the body where clinical material is widely and readily available and can serve as a window for the real in vivo immune system in a clinically relevant setting. We will therefore analyse the effects of otelixizumab on T cells from normal gut, antigen-specific gut T cells responding to gluten in celiac disease, and activated gut T cells in idiopathic inflammatory bowel disease. We will determine if otelixizumab is indeed non-activating on the already activated T cells in normal and diseased gut, if it delivers a negative signal, and the fate of the negatively regulated cells. We anticipate this information will determine if otelixizumab can be rolled out to treat inflammatory bowel disease, rheumatoid arthritis, asthma, and other idiopathic inflammatory conditions.</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>293149</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Crohns in Childhood Research Association</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>5F7E8102-00A5-4B38-AC57-D1C919113DF6</gtr:id><gtr:impact>Presented our data at the CICRA AGM

None so far</gtr:impact><gtr:outcomeId>F9BB16F8112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>81CC451D-A047-4B3B-8EC8-6F02D3F2340A</gtr:id><gtr:title>Microtubules are needed for the perinuclear positioning of aquaporin-2 after its endocytic retrieval in renal principal cells.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Cell physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0363-6143</gtr:issn><gtr:outcomeId>58ae02f44b91e6.70468443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8EB955D-260B-4B98-9F86-0B3D00EC66E0</gtr:id><gtr:title>Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sj&amp;ouml;gren's syndrome: clinical implications and effects of B cell-targeted therapies.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>58ae02f397b0f6.58067825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD8ABA8D-1EE8-49D1-BA4D-97BB949D7C3C</gtr:id><gtr:title>Transitional B cells: how well are the checkpoints for specificity understood?</gtr:title><gtr:parentPublicationTitle>Archivum immunologiae et therapiae experimentalis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-069X</gtr:issn><gtr:outcomeId>58ae02f3ee9305.36887413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>462A3390-8F4A-46DE-A28E-D4F59ED22907</gtr:id><gtr:title>Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c527f88ccb091966ae1ccaa57f48d497"><gtr:id>c527f88ccb091966ae1ccaa57f48d497</gtr:id><gtr:otherNames>Powell N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56cd88875267f4.14031491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2D9CEDE-2C88-45FB-8B72-DB5F4DF8475B</gtr:id><gtr:title>Reprogramming the immune system in IBD.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beebdfd81cb8f1e9b13595f4eb3debc8"><gtr:id>beebdfd81cb8f1e9b13595f4eb3debc8</gtr:id><gtr:otherNames>MacDonald TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>5460cd418b4cd3.64661876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD7D7C8B-4D9B-48E8-B764-A854A710F443</gtr:id><gtr:title>A role for gut-associated lymphoid tissue in shaping the human B cell repertoire.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5460cd41b2cee4.09197344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3E7BA07-4DD2-44CB-9329-5FBB941C1560</gtr:id><gtr:title>Inhibition of NF-?B signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58ae02f36ffdd7.54729736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>657E9E82-96AE-45A7-B89C-29FB27FCCF80</gtr:id><gtr:title>Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system.</gtr:title><gtr:parentPublicationTitle>Journal of inflammation (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1476-9255</gtr:issn><gtr:outcomeId>58ae02f42085d7.29717413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD682653-906D-4FE0-8100-E14059503E7A</gtr:id><gtr:title>Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58ae02f47c1499.83911389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8672C48-FDA9-4383-9ED2-3822B2297DD8</gtr:id><gtr:title>A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_540e15ee15eae10e7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20FC7D9C-333D-4748-B50B-E93BA4E2EAD6</gtr:id><gtr:title>Colonic lymphoid nodular hyperplasia in an adolescent.</gtr:title><gtr:parentPublicationTitle>Journal of pediatric gastroenterology and nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/13a5c401c9f6a3fab61e33f17b4c450d"><gtr:id>13a5c401c9f6a3fab61e33f17b4c450d</gtr:id><gtr:otherNames>Vossenk?mper A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-2116</gtr:issn><gtr:outcomeId>5460cd416374c2.83531070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>591E936D-6728-4B3C-893C-A7A9ED242B6A</gtr:id><gtr:title>Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd3c7bb2e0c18b309a753ad12f80deb4"><gtr:id>fd3c7bb2e0c18b309a753ad12f80deb4</gtr:id><gtr:otherNames>Biancheri P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56cd87781f5ec7.23977234</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800746</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>